Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Conditions:   BCR-JAK2 Fusion Protein Expression;   Blasts 20 Percent or Less of Peripheral Blood White Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Eosinophilia;   Hepatomegaly;   Hypereosinophilic Syndrome;   JAK2 Gene Mutation;   Splenomegaly;   TEL-JAK2 Fusion Protein Expression Intervention:   Drug: Ruxoli...
Source: ClinicalTrials.gov - January 11, 2019 Category: Research Source Type: clinical trials

Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus
Condition:   Hepatomegaly Intervention:   Sponsor:   Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2018 Category: Research Source Type: clinical trials

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory  Primary Amyloidosis Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis Sponsors:   Southwest Oncology Group;   National Cancer ...
Source: ClinicalTrials.gov - April 17, 2018 Category: Research Source Type: clinical trials

The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial
This study aims to determine the effects of green cardamom (Elettaria cardamomum) supplementation on blood glucose indices, lipids, inflammatory profiles, and liver function, especially by examining irisin, paraxonase-1 (PON1) and sirtuin-1 (Sirt1) in obese patients with NAFLD.MethodsThis trial is to be conducted at the polyclinic of the National Iranian Oil Company (NIOC) Central Hospital, Tehran. Eighty obese patients with NAFLD will be selected according to the eligibility criteria. The NAFLD diagnosis method is ultrasonography. Patients will be randomly divided into two groups by a random-number table (cardamom and pla...
Source: Trials - June 7, 2017 Category: Research Source Type: clinical trials